IMI announces nomination of Ron Henriksen to Board of Directors
April 13 2004 - 2:21PM
PR Newswire (US)
IMI announces nomination of Ron Henriksen to Board of Directors
TORONTO, April 13 /PRNewswire-FirstCall/ -- IMI International
Medical Innovations Inc. (TSX: IMI, Amex: IME) today announced that
Ron Henriksen has agreed to join the company's Board of Directors,
pending shareholder approval at the upcoming annual shareholders
meeting to be held on June 16, 2004. In the interim, IMI has
engaged Mr. Henriksen as a business consultant. "IMI is already
benefiting from Ron's wealth of industry knowledge and
international perspective. He has proven expertise in the U.S. and
global marketplaces, having completed more than 65 licensing,
research collaboration and acquisition agreements with a variety of
partners," said Dr. Brent Norton, President and Chief Executive
Officer. "Ron's guidance and counsel will certainly be invaluable
as we continue to establish IMI as a leader in the field of
predictive medicine." Mr. Henriksen brings more than 30 years of
experience in the healthcare field, working in the pharmaceutical,
biotechnology, consulting and venture capital industries. He is
currently Chief Investment Officer of Indianapolis-based Twilight
Ventures, LLC, which is a venture capital firm investing
exclusively in life science companies. Prior to joining Twilight
Ventures, he was President of ARTI (Indiana University's Advanced
Research & Technology Institute) from 1998 until 2002. Mr.
Henriksen served Eli Lilly and Company (NYSE:LLY) for more than two
decades in a variety of senior managerial and executive positions
in business development, marketing and finance, where he worked
closely with outside biotechnology, medical device and diagnostic
companies. In addition, Mr. Henriksen has acted as a consultant to
several medical device and biotechnology companies, providing
breadth and depth of expertise in business development, financing
and general management. In October 1993, BioPeople Magazine
selected him as the "number one business development executive in
the world". "IMI is an innovative and growing company with a novel
approach to identifying better predictors of cardiovascular disease
and cancer," said Mr. Henriksen. "I look forward to working with
the IMI team as the company brings its unique predictive medicine
products to market." Mr. Henriksen currently serves on the board of
directors of QLT, Inc. (TSX: QLT; NASDAQ: QLTI), MacroPore
Biosurgery, Inc. (XETRA: XMP), TGN Biotech Inc., CyberLearning
Labs, Inc. and BioStorage Technologies. He received a Bachelor of
Science degree in Industrial Administration at Iowa State
University and a Master of Business Administration (with
distinction) degree from the Harvard Business School. About IMI IMI
is a world leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of
life-threatening diseases, particularly cardiovascular disease and
cancer. The company's head office is located in Toronto, and its
research and product development facility is at McMaster University
in Hamilton, Ontario. For further information, please visit the
company's website at http://www.imimedical.com/. This release
contains forward-looking statements that reflect the company's
current expectation regarding future events. The forward-looking
statements involve risk and uncertainties. Actual events could
differ materially from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company's quarterly, annual and other
regulatory filings. DATASOURCE: IMI International Medical
Innovations Inc. CONTACT: Sarah Borg-Olivier, Director,
Communications, T: (416) 222-3449,
Copyright